Care Options
Equine Herpesvirus 1 Vaccine: What to Know and Where to Start
The equine herpesvirus 1 (EHV-1) vaccine helps protect horses against respiratory disease and abortion, but it does not prevent the neurologic form of the infection.
Key takeaways
The equine herpesvirus 1 (EHV-1) vaccine helps protect horses against respiratory disease and abortion, but it does not prevent the neurologic form of the infection.
- EHV-1 is a contagious virus that affects horses and can cause respiratory illness, pregnancy loss, and serious neurologic complications.
- Vaccination is an important part of prevention, particularly for breeding mares, young horses, and animals that travel or come into contact with other horses.
- However, vaccination does not replace isolation, hygiene, and other biosecurity measures.
- Understanding which vaccines are available, what they protect against, and when they are appropriate can help horse owners make informed decisions about equine health.
What the Vaccine Is and What It Protects Against
The EHV-1 vaccine is a veterinary vaccine designed to help horses develop immunity against equine herpesvirus type 1.
EHV-1 belongs to a group of viruses that can cause respiratory infections, reproductive complications, and neurologic disease.
Vaccines are available to help protect against two important forms of EHV-1 disease:
• Respiratory disease: Vaccination can reduce the severity of respiratory illness and help limit viral shedding.
• Reproductive disease: Certain vaccines are licensed to help prevent abortion associated with EHV-1 infection in pregnant mares.
There is currently no licensed EHV-1 vaccine labeled to prevent equine herpesvirus myeloencephalopathy (EHM), the neurologic form of the infection. A vaccinated horse can still develop EHV-1 infection and neurologic complications.
The American Association of Equine Practitioners (AAEP) classifies EHV vaccination as risk-based. This means vaccination decisions depend on the horse's age, health, pregnancy status, travel, exposure, and living conditions.
How It Works and Why EHV-1 Spreads
EHV-1 vaccination works by exposing the horse's immune system to viral antigens so it can recognize the virus and respond more effectively after exposure.
The resulting immune response can reduce clinical disease, viral replication, and the amount of virus shed through nasal secretions.
EHV-1 spreads through several routes:
• Direct contact: Horses can transmit the virus through contact with infected nasal secretions.
• Respiratory exposure: Coughing and snorting can release infectious respiratory droplets.
• Contaminated equipment: Shared water buckets, feed containers, grooming tools, tack, and other equipment can transfer the virus.
• Contaminated materials: Aborted fetuses, placental tissue, and fetal fluids can contain infectious virus.
EHV-1 and EHV-4 can also establish latent infections. A horse can carry the virus without showing signs of illness, then experience viral reactivation during periods of stress. Reactivation can lead to renewed viral replication and shedding, even in a horse that previously appeared healthy.
Main Types of EHV Vaccines
Equine herpesvirus vaccines fall into two main categories:
Inactivated vaccines
These vaccines contain killed viral material that stimulates an immune response without introducing replicating virus. Some products are licensed for respiratory disease prevention, while others have indications for both respiratory disease and EHV-1-associated abortion.
Some inactivated vaccines combine EHV-1 and EHV-4 antigens. The product label determines which diseases the vaccine is intended to help prevent.
Modified-live vaccines
These vaccines contain a modified form of the virus that stimulates an immune response. One licensed modified-live EHV-1 vaccine is available in the United States for use in healthy horses to help prevent respiratory disease.
The modified-live product does not carry a label indication for preventing EHV-1-associated abortion.
The AAEP distinguishes these vaccine types because their indications and effects on viral shedding differ. Vaccines with abortion-prevention indications and certain other products can also help reduce nasal shedding and viremia.
Vaccination cannot eliminate latent EHV-1 infection or guarantee that an infected horse will not shed the virus.
What EHV-1 Looks Like in Real Life
EHV-1 infection can produce different symptoms depending on the affected body system, the horse's age, and its immune response.
Some infected horses show no obvious illness, while others develop respiratory, reproductive, or neurologic complications.
Respiratory symptoms
Respiratory disease is particularly common in young horses, including foals, weanlings, and yearlings.
Signs include:
• Fever
• Nasal discharge
• Coughing
• Loss of appetite
• Lethargy or depression
• Swollen lymph nodes
• Swelling in the lower limbs
Fever can appear before respiratory symptoms and may be the only early sign of infection. Regular temperature monitoring helps identify illness before more noticeable symptoms develop.
Reproductive complications
EHV-1 can cause abortion in pregnant mares, particularly during later pregnancy. A mare can experience pregnancy loss without showing obvious respiratory illness or other warning signs beforehand.
Infected mares can also give birth to weak or severely ill foals. In-utero infection can result in neonatal disease involving respiratory distress, weakness, fever, and other serious complications.
Vaccination with an appropriately licensed abortion-prevention vaccine helps reduce reproductive disease risk.
Neurologic complications
The neurologic form of EHV-1 is called equine herpesvirus myeloencephalopathy (EHM). It develops when infection affects blood vessels supplying the central nervous system, causing inflammation, impaired circulation, and damage to nervous tissue.
Signs can include:
• Weakness in the hind legs
• Stumbling or difficulty coordinating movements
• Loss of balance
• Difficulty standing
• Loss of tail muscle tone
• Difficulty urinating or urine dribbling
• Inability to rise in severe cases
Neurologic symptoms can develop after fever or respiratory illness, but they do not always follow a recognizable pattern.
Sudden weakness, loss of coordination, or inability to stand requires urgent veterinary attention.
Risks and Limitations of the Vaccine
EHV-1 vaccines offer useful protection against certain forms of disease, but they do not provide complete immunity.
Their effectiveness depends on the vaccine product, the horse's immune response, and its exposure risk.
Protection is not guaranteed
Vaccinated horses can still become infected with EHV-1. Vaccination can reduce the severity of respiratory disease and help limit viral shedding, but it does not reliably prevent infection or transmission.
Post-vaccination antibodies also do not necessarily indicate complete protection against clinical disease.
No licensed protection against EHM
The most important limitation is the absence of a licensed vaccine specifically labeled to prevent EHM. A horse that has received routine EHV-1 vaccinations can still develop neurologic disease.
Vaccination can contribute to reducing viral circulation within a horse population, but it cannot replace quarantine and infection-control procedures.
Possible reactions after vaccination
Some horses experience temporary reactions after receiving an EHV vaccine, including:
• Mild fever
• Lethargy
• Discomfort or soreness at the injection site
The November 2025 EHM incident guidance identifies post-vaccination fever and lethargy lasting 24 to 72 hours or longer as possible reactions. Fever can complicate outbreak monitoring because it can resemble an early sign of EHV-1 infection.
A horse's health, previous vaccine reactions, and exposure history should be considered when planning vaccination.
What to Do About EHV-1 Vaccination
A vaccination plan should reflect the horse's age, reproductive status, previous vaccinations, and likelihood of exposure.
The AAEP provides risk-based guidance for developing vaccination schedules.
Understand the recommended schedule
Common AAEP recommendations include:
• Horse or group — General vaccination guidance
• Foals — Begin a primary series at 4 to 6 months of age, with subsequent vaccinations according to the product and schedule.
• Horses with unknown vaccination history — Start a primary series, generally involving 2 or 3 doses depending on the product.
• Young horses under 5 — Revaccination at 6-month intervals is recommended.
• Horses at breeding facilities — More frequent vaccination is recommended because of exposure risks.
• Performance and show horses — Revaccination at 6-month intervals is recommended in high-risk situations.
• Pregnant mares — Use an inactivated vaccine licensed for abortion prevention according to the recommended pregnancy schedule.
For foals, the AAEP recommends a three-dose primary series, beginning at 4 to 6 months, with the third dose at 10 to 12 months.
For pregnant mares, the recommended schedule for an inactivated abortion-prevention vaccine includes vaccination during the fifth, seventh, and ninth months of gestation. Additional vaccination during the third month is also recommended by some veterinarians.
Previously vaccinated, non-breeding adult horses with low exposure risk do not necessarily need frequent EHV boosters. Horses in high-movement environments have different vaccination needs.
Strengthen everyday biosecurity
Vaccination should be part of a broader disease-prevention plan.
Practical measures include:
• Isolating new or returning horses for at least 21 days.
• Avoiding nose-to-nose contact with unfamiliar horses.
• Providing individual water and feed buckets.
• Cleaning and disinfecting shared equipment.
• Washing hands after handling potentially infected horses.
• Monitoring temperatures, particularly after travel or known exposure.
• Keeping pregnant mares separate from groups with greater exposure risk.
Horse owners should maintain vaccination records and document travel, exposure, and illness history. Competition facilities may also have vaccination requirements that affect when a horse needs its next booster.
Responding to a suspected outbreak
Vaccination is not a treatment for an existing EHV-1 infection. If a horse develops a fever or respiratory symptoms after possible exposure, isolation and veterinary assessment take priority.
During an EHM incident, routine vaccination is not recommended because a post-vaccination fever can complicate quarantine and monitoring. Vaccinating non-exposed horses during an outbreak requires careful consideration and coordination with regulatory officials.
Strict biosecurity, isolation of infected horses, and monitoring of exposed animals remain the main outbreak-control measures.
Ask your veterinarian to match the vaccine's licensed indication and vaccination schedule to the horse's age, pregnancy status, previous vaccinations, and exposure risk.
Where to Get Help
An equine veterinarian is the primary resource for EHV-1 prevention, diagnosis, vaccination, and treatment.
Veterinary assessment is particularly important when a horse has a fever, respiratory symptoms, or a known connection to an infected animal.
If infection is suspected, diagnostic testing can help confirm the condition. Veterinarians commonly use polymerase chain reaction (PCR) testing on nasal swabs and blood samples to detect EHV-1.
Cornell University's Animal Health Diagnostic Center provides equine herpesvirus testing services and diagnostic guidance for suspected clinical cases.
For a suspected outbreak, additional support may come from:
• Equine veterinarians: Assess symptoms, arrange diagnostic testing, and coordinate treatment.
• Equine hospitals: Provide advanced care for horses with severe respiratory or neurologic complications.
• State animal health officials: Provide guidance on disease reporting, quarantine, and movement restrictions.
• USDA Animal and Plant Health Inspection Service (APHIS): Provides disease information and outbreak-control resources.
• American Association of Equine Practitioners (AAEP): Provides professional vaccination guidelines and infectious-disease resources.
Do not transport a horse with suspected EHV-1 until veterinary or animal health officials provide movement instructions.
Frequently asked questions
Is EHV-1 the same as EHV-4?
No. EHV-1 and EHV-4 are related but distinct equine herpesviruses. EHV-1 can cause respiratory disease, abortion, and neurologic complications, while EHV-4 primarily causes respiratory illness. Some vaccines contain antigens for both viruses.
Can horses spread EHV-1 without showing symptoms?
Yes. Horses can carry latent EHV-1 without visible illness. Stress can reactivate the virus, allowing an apparently healthy horse to shed and transmit it.
Does equine herpesvirus infect humans?
No. EHV-1 is an equine disease and does not pose a health risk to people. However, people can transfer the virus between horses through contaminated clothing, hands, footwear, and equipment.
Can horses recover from EHV-1?
Many horses with respiratory EHV-1 infections recover without lasting complications. EHM is more serious and can cause permanent neurologic damage or death, particularly in severely affected horses.
Editorial standards
Who wrote this guide
Written by VetWayfinder Editorial Team.
Every factual statement is tied to a cited source listed below. Report an error through the corrections page.
Sources
Each source supports at least one factual statement in this guide.
